A Phase 2 interventional study of ONO-4538 and oxaliplatin in Pan-tumor, sponsored by Ono Pharmaceutical Co., Ltd.. Recruiting at 44 sites in 3 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.
Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
480 mg of ONO-4538 IV Q4W or 240 mg of ONO-4538 IV Q2W per the investigator's choice
Drug: ONO-4538
ONO-4538 at 360 mg IV Q3W or 480 mg IV Q4W, and Combination therapies (S-1 + Oxaliplatin \[SOX\] therapy , Capecitabine + Oxaliplatin \[CapeOX\] therapy , Bevacizumab, Temozolomide, Ipilimumab + SOX therapy, Ipilimumab + CapeOX therapy or ONO-7703) selected by the principal investigator or subinvestigator in the Parent Study will be continued in this study.
Drug: ONO-4538 · Drug: oxaliplatin · Drug: S-1 · Drug: capecitabine · Drug: bevacizumab · Drug: temozolomide · Drug: Ipilimumab · Drug: ONO-7703
IV infusion over 30 minutes
IV infusion over 2 hours
Drug pages: Tegafur · Gimeracil · Oxonic Acid
Administered orally twice daily
Administered orally twice daily
IV infusion over 30 minutes
Administered orally once daily for 5 days every 28 days
IV infusion over 30 minutes
Administered orally twice daily
Incidence of Adverse Events (Aes)
(non)
Time frame: From Day 1 up to 28 days after the end of the treatment phase
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2020 (actual). Primary completion is estimated for Dec 2027, 87 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab
Ono Pharmaceutical Co., Ltd. →